Cost-effectiveness studies will come later. Nonetheless since this later set of problems is more in my line, the bulk of the paper will be devoted to exploring what seems to me to be the likely requirements, difficulties, and opportunities for cost-effectiveness studies in this area. What is to follow can be divided into three parts: First, a review of some of the relevant work of economists and others that concern themselves with costs and benefits in the health area. This portion of the talk will concern itself mostly with the economists who have been mainly interested in the economic implications of improved health. Second, I would like to go over a BOB-prepared example of a Any views expressed in this paper are those of the author. They should not be interpreted as reflecting the views of The RAND Corporation or the official opinion or policy of any of its governmental or private research sponsors.
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program budget for health programs administered by HEW as a framework within which to go on to discuss possible types of cost benefit analysis that might be undertaken of these programs.
Third, I would like to close with a discussion of what appear to me to be main problems and opportunities for cost benefit analysis in the health area.
A REVIEW OF RELEVANI' RESEARCH I would like to discuss two sorts of research: First, very general research on the economic value of human beings; second, particular calculations that have been attempted of the cost and benefits of the eradication of specific diseases.
In the past there have been many attempts made by economists, statisticians and actuarics to estimate the economic value of human beings (a problem that comes up repeatedly in military problems, safety programs of all sorts, etc., as well as in the health area). Let me quote Professor Klarman in this connection:
CONSUMER BENEFIT: A common difficulty in measurement is that few (if any) health services are pure investment goods or consumpti-)n goods that yield the same degree of health improvement. It is conventional to recognize the benefit in consumption derived from most health and medical care expenditures (such as reduction of pain, discomfort, etc.), to comment on the difficulty of measuting it, and then to dismiss it. What receives weight (and space) is what is measurable; and that is not necessarily important. Since the measurable segments--output loss and medical care expenditures--are not equally important in all programs being evaluated, their sum is not likely to bear a consistent relationship to the loss of consumption benefit. Attaching a value to the latter, lest it be forgotten (or treated as zero), is both a sobering and challenging task.
For this purpose it is helpful to recall that consumers are frequently willing to incur expenditures, medical and other, that do not promise an increase in earnings or an offsetting saving in expenditures. Suppose a person's lifetime income were guaranteed to him and his heirs, and health and medical services were furnished free of charge. Notwithstanding, would not many persons be willing to spend some money to avoid syphilis or to be cured of it in the early stages? It seems plausible to assume an affirmative answer. The-question is, how much would they be willing to spend? Good sources on this broad area are "Health as an investment," This represents a direct cost of medical services during that year of $1.2 billion, and an indirect cost of $10.0 billion. This latter estimate is based on the notion that if cancer had been totally eradicated sometime in the past, and in the calculations I believe the year is 1900, a good many people who had died in the past would still be in the work force. The additional number of people in each age group multiplied by the average earning in that age group summed over all age groups is used to obtain an estimate. This comes to $9.0 billion for cancer, the remainder of the indirect costs are due to morbidity. This sort of calculation is used to show how important economically this and the other diseases are and to form some basis for arguing for investment in measures leading to improved care.
For comparison, Weisbrod, using the more usual method of calculation based upon the sum of the discounted stream of future earnings, gives an estimate of the loss due to cancer in 1954 of about $2.6 billion per year (using 4 per cent discounting rate).
Let me r-view some of the things that this type of calculation has left out. First, depending on the nature of the improved treatment involved, not all of the direct costs cosuld be saved. Unless it would be possible to prevent cancer from ever occurring, there will be costs of treatment, In fact, improved care might be much more expensive than currenL treatment, or possibly much cheaper. The point is one needs an estimate of treatment cost.
On the other hand, by looking only at the costs of a particular year, one is underebLianting the possible benefits of obtaining a cancer cure.
In the health area as elsewhere cost effectiveness calculations involve comparing the whole stream of benefits, discounted back to the point at which decisions are being made.
Presumably in more realistic
calculations, what would occur as a result of medical research, or the employment of improved method of care, is not a dramatic shift of the cancer ueath rate from whatever it is to zero, but a gradual decline at some rate over lengthy period. This gradual decline and the discounting the future benefits would mean that the close-in benefits are likely to be small while the larger future benefits are heavily discounted. Moreover, there is a problem as to future wage rates, assuming significant increase in the working population, but this would in any case be itself a difficult projection to make (moreover the retirement age might be younger in the future).
In the calculations being criticized here, it is assumed that something like six million additional people would have been in the labor force.
With respect to cost, the discounting procedure, if the costs have occurred in the past, of course, has the effect of inflating them.
Thus, in the current case, where it is assumed that somehow the cure for cancer was found prior to 1900, R&D expenditures in the 1880s and 1890s, if accumulated at approximately 5 per cent as a basis of comparison with current presumed benefits, would be very large.
Even if one assumes that the R&D program was especially successful, short-lived, and occurred immediately prior to 1900, an interest rate of 5 per cent would mean that any R&D expenditures ought to be multiplied by a factor of 22, when being compared with the yearly benefit. Of course, again what this expenditure has to be compared with is not the single year, but the whole sequence of benefits which would have been rather small in the early part of the century. What one ought to compare is something like:
where GNP (t) takes account of any reduction of capital stock caused by diversion of investment to incremental treatment expense--to prepare such an estimate would be an interesting economics problem in itself.
In the literature there is a dispute over whether to deduct subsistence from earnings in calculating the value of saving lives.
Some suggest it is not appropriate in the United States, but ought to be done for underdeveloped countries with excess population. The use of earnings would be correct, however, if GNP (t) can be calculated since it would take account oi changes in the labor capital ratio implied in increased investment in health.
As a summary of my reactions to the existing literature that deals with estimates of the cost of disease or with cost-benefit calculations in the health area let me say:
1. While a start has been made in thinking through the rationale of such estimates and calculations actual estimates and calculations of costs and benefits are seriously incomplete in most cases and often are wrong in principle.
2.
With respect to estimates of benefits it is especialiy important that: (a) some means be found to reflect the consumption 
PROBLEMS OF COST-BENEFIT ANALYSIS
The rationale of the grouping in this program budget is to put together programs which have similar objectives. However, it will probably take a good deal of work if anything like this program budget is adopted to apportion the expenditures as passed by the Congress into the above specified program packages. The rationale of putting similar programs together is not only that they have the same general objectives, but also that one is likely to be interested in tradeoffs as between diffezent programs in the same program package.
This again is where one comes up against the problem mentioned Given salary scales for doctors, dentists, nurses, and all other medical specialities (assuming that these reflect the demand for these personnel) and estimates of the effectiveness of government expenditure in increasing tfie supply of these personnel, it would be possible to look at the optimal balance of expenditures as amongst all of these typeG of training.
With respect to hospital construction, cost benefit studies of hospital programs could be carried on so as to get optimal effectiveness from the construction funds. Moreover, there are problems of coordination and reconciling the way in which two or more government programs interact. It is alleged that studies of the geographic distribution of (a) the increased demand for hospital services implied by the Medicare Bill and (b) the increased supply likely to result from the Hill-Burton hospital construction bill do not coincide very well. This is an area where analysis might indicate how to get more efficient use of the hospital construction monies.
Adding hospital beds does not necessarily insure that they will be in fact used. Indeed, there is a possible tradeoff between programs designed to increase the supply of hospital services c.vailable and other programs designed to increase the effective use of existing hospitals. This is only one aspect of a very general problem. A medical friend of mine conjectures that the single most cost-effective program in the United States today would be one designed to get more people into the hands of the medical profession and out of the hands of chiropractors, healers, quacks, fortunetellers. That is, there is at this moment likely to be more payoff in getting more people into the habit of using the average competence of current trained medical practitioners than in upgrading the training and capabilities of the trained medical profession.
The final item in this general package containing programs designed for Improvement of Quality in Organization, is exemplified by the Heart, Cancer and Stroke program. This is representative of a type of program which should become considerably more numerous, more important and a larger part of the U.S. government health budget in future years. The United States is currently expending a major effort in the area of basic medical research. Let me stress that most of the research is basic research. Most of it is not specifically disease-oriented, but related to understanling biological processes.
The notion being that at a later time the kno.ledge obtained will allow the development of effective treatment of the major diseases.
Those in charge of the NIH program assert that this is the preferred strategy of attack at the moment. If this program is successful, at a later time it will be necessary to go on to study how best to apply this knowledge to the prevention, cure, treatment of specific diseases. At this stage, what might be thought of as the developmeent stage in military R&D terminology will have been reached. Once that stage is reached, one will want to know how to best allocate the development money. Which diseases should be emphasized? Some notion of the economic importance of various diseases and public preferences to be protected against one disease rather than another would be relevant in choosing.
It is easy to imagine that the public would desire to avoid, if possible, especially disfiguring or painful diseases even if they did not currently have much effect on potential GNP. Some way must be found to reflect such preferences in any costbenefit studies designed to assist in the allocation of funds for the development of improved treatment of various diseases. But it will be important that the solicitation or measurement of public preferences be undertaken in a systematic and reflective way, since the history of much public support for the care and treatment of specific diseases appears to me to have had a large element of sentimentality in it as the result of publicity campaigns by specific groups interested in particular diseases.
Another potential area of study might concern itself with the problem of the best way to introduce newer methods of treatment, better techniques, etc., to the medical profession at large. Thus, for example, in the case of the Heart, Cancer and Stroke Programs, a study might be undertaken of a variety of programs before making the decision as to the most cost-effective program. Each program might 1Ž designed on an equal cost basis and judged for effectiveness in terms of the degree to which it was likely to improve the quality of medical care throughout the country.
There clearly would be a number of criteria problems (e.g., How is Improved quality of medical care to be measured?).
In some cases, one could try to do it directly in terms of estimated improvement in death rates, morbidity rates for particular diseases, by area.
One thing I note in the health area is a reluctance to make estimates of important technical parameters, payoffs, costs, that are necessary to any evaluation of the total cost or benefit of specific programs. For example, the cost-benefit analysis in the health area I have seen, often mentioned the desirability of includLng such-and-such an effect or factor in the evaluation of the cost or benefit of a particular program, but they rarely, if ever, include quantitative estimates of these aspects. Of course it can be claimed that the effects of specific programs are very uncertain and therefore it is difficult to make the required estimates. No doubt it is, but so are many similar estimates in the defense field difficult to make. Section IV "Health Protection and Prevention" contains a variety of programs relating to regulation, inspection, quarantine activities, specific programs for the control of yellow fever, TB, venereal diseases, etc. Here again, it seems to me that the Government's programs are only a small part of the health protection and prevention measures taken in ihe country, and that one may well be confined to studying the activities for the particular programs and evaluating them on a cost-benefit basis.
With regard to some of the communicable diseases;
for example, yellow fever and the attempt to eradicate the Aedes aegypti mosquito, some interesting questions may be posed as to judging alternative programs and their promise for achieving the objectives of these programs. The second observation I would have is that in a number of these cases, attempts are being made, essentially to get the probability of contacting specific diseases down to zero. This always pose.s an acute problem, since, as the probability approaches zero, it becomes increasingly hard to measure, and increasingly difficult to assess the marginal value of specific changes in enforcement or other measures. This suggests some real thought of how to go about these programs, and what is the best measurement of the effectiveness of programs for eradication or social prevention of specific diseases.
Again this is a very general problem: How far to try to go in trying to eradicate a particular disease? In the case of plague, we have to live with an environment which provides sources of infection and control the cases that occur. It would be too costly to reduce the probability of a plague case to zero through destruction of all host rodents. A cost benefit approach to this type problem which displayed the tradeoffs involved in specific programs between prevention and treatment would be interesting.
With respect to the next category of environmental protection and control, there would seem to be a number of interesting opportunities. At least those of us who live in places like Los Angeles are quite aware of the air pollution problem.
There are large social and economic problems relating to water pollution, air pollution; methods of evaluating and designing programs in these areas on a cost benefit basis need to be developed. Special attention should be given to tradeoffs involved in these areas when these problems are examined in broad perspective. Not only do new technologies need to be considered in reducing the pollution problem, but as the recent PSAC report on the pollution problem suggests new taxation --incentive schemes may be needed. In any case these broad environmental problems need to be looked at in their broadest perspective and on a systematic basis.
FINAL COMMENTS
I have tried to indicate some of the areas in which cost-benefit analyses seem most promising and some of the major problems likely to arise in doing such analyses in these areas. I am impressed by the rather undevelopee state of cost-benefit analyses in the health area and by some of the problems that will have to be overcome before useful analyses can be done on many of the problems. However, it seems likely to me that with the U.S. government's increasing role in the health field that the payoff to good analysis will be very large.
